These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30027756)

  • 1. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
    Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
    Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Bao T; Goloubeva O; Pelser C; Porter N; Primrose J; Hester L; Sadowska M; Lapidus R; Medeiros M; Lao L; Dorsey SG; Badros AZ
    Integr Cancer Ther; 2014 Sep; 13(5):396-404. PubMed ID: 24867959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
    Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
    Garcia MK; Cohen L; Guo Y; Zhou Y; You B; Chiang J; Orlowski RZ; Weber D; Shah J; Alexanian R; Thomas S; Romaguera J; Zhang L; Badillo M; Chen Y; Wei Q; Lee R; Delasalle K; Green V; Wang M
    J Hematol Oncol; 2014 May; 7():41. PubMed ID: 24886772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
    Han X; Wang L; Shi H; Zheng G; He J; Wu W; Shi J; Wei G; Zheng W; Sun J; Huang H; Cai Z
    BMC Cancer; 2017 Jan; 17(1):40. PubMed ID: 28068938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
    Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
    Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
    Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
    Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study.
    Nishiwaki U; Yokote T; Hatooka J; Miyoshi T; Iwaki K; Masuda Y; Fujimoto M; Ueda M; Kinoshita Y; Arita Y; Shimizu M; Yamada T; Tanabe K; Akioka T; Imagawa A
    Leuk Lymphoma; 2020 Mar; 61(3):707-713. PubMed ID: 31642372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.
    Mandıroğlu S; Cevik C; Aylı M
    Acupunct Med; 2014 Apr; 32(2):194-6. PubMed ID: 24389811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.
    Zhang Y; Zhang H; Wang J; Wei X; Qu YI; Xu F; Zhang L
    Oncol Res; 2024; 32(5):955-963. PubMed ID: 38686049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach.
    Yang Y; Zhao B; Lan H; Sun J; Wei G
    Crit Rev Oncol Hematol; 2024 May; 197():104353. PubMed ID: 38615869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
    Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
    Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
    Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
    Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
    Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
    Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.